Zanubrutinib-Obinutuzumab Doubles PFS in Follicular Lymphoma

Over the 12-month follow-up, significantly more patients who received the combination demonstrated a durable response compared with those who received obinutuzumab alone.
Medscape Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *